AstraZeneca jab has 76% efficacy against symptomatic Covid-19, study finds

The AstraZeneca vaccine has 76% efficacy against symptomatic Covid-19, the company said as it updated analysis of its Phase III testing (Yui Mok/PA)

AstraZeneca says its vaccine has 76% efficacy against symptomatic Covid-19, after the firm updated analysis of the third phase of testing.

The revised number follows figures released on Monday reporting the jab was 79% effective, which US federal health officials expressed concern were based on “outdated information”.